Innovative and accredited continuing medical education for today’s practicing clinicians.
CME Institute is trusted by physicians across medical specialties for premium continuing education that yields the highest educational outcomes. These ACCME-accredited activities make the latest research, novel therapies, and clinical best practices accessible and approachable for physician, NP, PA, and PharmD learners.
- Expert-led insights to improve patient outcomes
- Multi-modal courses to suit all learning styles
- Timely topics for relevant application to practice
- Razor-focused approach to innovation that includes documentary-style video and micro-learning Tweetorials
- A commitment to collective mindfulness
Recent courses
Predicting suicide is difficult, as suicidal behavior is not linked solely to any single behavior or psychiatric diagnosis. This study compared risk of suicidal behavior among a transdiagnostic sample of Veterans with varying disorders and behaviors.
|
Prompt treatment of early-stage Alzheimer disease (AD) can curb symptom progression. Tests for biomarkers, new symptomatic treatments and disease-modifying agents, and the addition of the preclinical stage to AD diagnostic criteria can aid in earlier disease recognition and building treatment plans.
|
Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.
|
Early-stage diagnosis of Alzheimer disease leads to prompt treatment initiation and better patient QoL. Learn about new guidelines and technology advances and what’s on the horizon from authorities in the field.
|
Long COVID symptoms are both physical and mental in nature among children and adolescents and have the potential to affect long-term functioning and increase the overall burden on health care delivery.
|
Patients with generalized myasthenia gravis (gMG) receive multiple immunosuppressive therapies, but with incomplete suppression of IgG autoantibodies. Review this update on gMG to learn about novel therapies that can more effectively suppress IgG autoantibodies through a novel mechanism of action to help your patients achieve better clinical outcomes.
|
Patients with generalized myasthenia gravis (gMG) receive multiple immunosuppressive therapies, but with incomplete suppression of IgG autoantibodies. Read this rapid update in gMG to learn about novel therapies that can more effectively suppress IgG autoantibodies through a novel mechanism of action to help your patients achieve better clinical outcomes.
|
Measurement-based care (MBC) can improve patient outcomes, but data on its use in psychosis are sparse. This study examined the use of patient-reported outcome measures in veterans with psychosis to identify candidate measures for psychosis-related MBC.
|
Night eating syndrome is a condition that requires early identification and management, especially among adolescents who develop symptoms during the transition into adulthood.
|